 Clinical virologic effects recombinant human granulocyte-macrophage colony-stimulating factor patients chemotherapy human immunodeficiency virus-associated non-Hodgkin lymphoma results randomized trial Thirty patients human immunodeficiency virus HIV non-Hodgkin lymphoma NHL chemotherapy cyclophosphamide doxorubicin vincristine prednisone CHOP subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor rGM-CSF additional therapy Recombinant rGM-CSF dose micrograms/kg/d days early rGM-CSF first patients days rGM-CSF chemotherapy cycle subsequent patients control group delayed rGM-CSF group mean nadirs absolute neutrophil count /L mean durations neutropenia days chemotherapy cycles neutropenia fever days fever neutropenia reductions chemotherapy dosages frequent delays chemotherapy administration significant differences patients control group early rGM-CSF group Median levels serum antigen baseline values control rGM-CSF groups week administration first cycle chemotherapy third week chemotherapy median antigen levels baseline control group baseline values rGM-CSF group stimulation HIV replication effect change HIV activity clinical outcome treated patients clinical significance finding unclear Complete response rates control rGM-CSF early rGM-CSF groups survival times months